Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PAY +21%, AVAV +18.6%, VVX +11.3%, TGT +8.5%, RSKD +6.3%, FWRG +6%, CRGY +4.5%
Other news:
- APGE +31.8% (interim results from phase 1 Healthy Volunteer Trial for APG777)
- RGNX +25.9% (initial efficacy data from Affinity Duchenne trial)
- ALNY +2.6% (Alnylam Pharma and Roche (RHHBY) report positive topline results from the Phase II KARDIA-2 study)
- LLAP +2.5% (awarded a $15.2 million contract to supply Ambassador Class satellite platforms)
- WTTR +2.3% (appoints new CFO)
- BWXT +1.6% (awarded $45 bln DoE contract)
- VIAV +1.2% (acquires Spirent Communications for ~$1.28 bln)
- DXCM +1.1% (Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD)
- SAIA +1% (Q1 LTL operating data) .
Analyst comments:
- SPRY +6.1% (upgraded to Outperform from Market Perform at Leerink Partners)
- T +1% (upgraded to Outperform from Peer Perform at Wolfe Research)